Hayes Advocates Evidence-Based Methods to Diabetes Care

For that 24 million Americans coping with diabetes and also the 57 million more that are prone to developing diabetes type 2, treatment approaches still evolve as new research targets better methods to improve patient outcomes. During American Diabetes Month in November, Hayes, Inc. (http://www.hayesinc.com) urges clinicians and patients to understand whenever possible about new and emerging treatments for diabetes type 2 and also to assess the evidence prior to making important medical decisions.

Using the discovery of recent medications, novel methods to deliver insulin, and weight-loss surgeries that could have the possibility to eradicate diabetes type 2 in obese patients, it may be a hardship on patients and their healthcare providers to find out which approach is better.

“With lifelong conditions for example diabetes, there’s a powerful curiosity about technology for example new drugs and insulin-delivery systems,” says Jill Shuman, MS, RD, Senior Research Analyst at Hayes, Inc. along with a Registered Dietitian. She cautions patients and providers to proceed carefully. “Although anecdotal evidence may show that novel approaches lead to good patient outcomes for the short term, it’s much more vital that you study the long-term evidence to determine how new procedures and medicines will affect patients after five or ten many years of follow-up.”

Risks and benefits often aren’t fully identified until a large number of people have come across a specific treatment. It was the situation using the antidiabetes medication troglitazone (Resulin®; Parke-Davis/Warner-Lambert, Morris Plains, NJ), that was taken off the U.S. market in 2000 after being associated with increased liver injury. Recently, the Fda (FDA) voted to create rosiglitazone (Avandia®; GlaxoSmithKline, Research Triangle Park, NC) available only within restricted-access program after long-term study data suggested that it’s related to ischemic cardiovascular disease.

Comparative-effectiveness review (CER), which directly compares one intervention with another, is yet another tool open to patients, payers, and providers. “The direct comparison of treatments that’s fundamentally of CER identifies which intervention offers the best benefits and which poses the best harms. This permits consumers and providers to create informed healthcare decisions,” says Shuman.

About Hayes, Inc.: Hayes, Inc. is definitely an independent health technology research and consulting company focused on promoting better health outcomes by using evidence. Hayes performs unbiased, evidence-based health technology assessments from the safety and efficacy of recent, emerging, and controversial health technologies and evaluates the impact of those technologies on healthcare quality, utilization, and cost. Hayes’ worldwide clients include hospitals, healthcare systems, government departments, employers, and managed care organizations. Hayes, Inc. monitors changing methods to diabetes care through its News Service and reports breaking developments on its website.